Biodesix Inc (BDSX) stock

BDSXNasdaqServices-Medical LaboratoriesFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30

$9.79−0.33 (-3.26%)

Close on Nov 12, 2026Market cap $103.30MP/E –Yield –

Biodesix operating margin

Operating margin is operating income as a percentage of revenue.

Biodesix's operating margin for the twelve months ending Sep 30, 2026 was -18.7%. For fiscal 2025 it was -31.5%, against -48.4% the year before. The highest annual figure on record is -31.5% in fiscal 2025.

Annual operating margin

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	-31.5%	+16.9
FY2024	Dec 31, 2024	-48.4%	+35.9
FY2023	Dec 31, 2023	-84.2%	+48.2
FY2022	Dec 31, 2022	-132.4%	−57.3
FY2021	Dec 31, 2021	-75.1%	−24.8
FY2020	Dec 31, 2020	-50.3%	+58.6
FY2019	Dec 31, 2019	-108.9%	–

Quarterly operating margin

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q3 FY2026	Sep 30, 2026	-25.4%	+7.0
Q2 FY2026	Jun 30, 2026	-20.1%	+28.5
Q1 FY2026	Mar 31, 2026	-24.3%	+26.6
Q4 FY2025	Dec 31, 2025	-6.8%	+25.7
Q3 FY2025	Sep 30, 2025	-32.4%	+14.9
Q2 FY2025	Jun 30, 2025	-48.6%	−2.6
Q1 FY2025	Mar 31, 2025	-50.9%	+23.5
Q4 FY2024	Dec 31, 2024	-32.5%	+14.3
Q3 FY2024	Sep 30, 2024	-47.3%	+5.8
Q2 FY2024	Jun 30, 2024	-46.0%	+46.1
Q1 FY2024	Mar 31, 2024	-74.4%	+106.4
Q4 FY2023	Dec 31, 2023	-46.8%	+97.7
Q3 FY2023	Sep 30, 2023	-53.2%	+42.4
Q2 FY2023	Jun 30, 2023	-92.0%	+14.1
Q1 FY2023	Mar 31, 2023	-180.8%	+40.0
Q4 FY2022	Dec 31, 2022	-144.6%	+17.1
Q3 FY2022	Sep 30, 2022	-95.5%	+104.9
Q2 FY2022	Jun 30, 2022	-106.2%	−17.1
Q1 FY2022	Mar 31, 2022	-220.8%	−201.5
Q4 FY2021	Dec 31, 2021	-161.7%	−151.9
Q3 FY2021	Sep 30, 2021	-200.4%	−132.6
Q2 FY2021	Jun 30, 2021	-89.1%	+43.5
Q1 FY2021	Mar 31, 2021	-19.3%	+145.9
Q4 FY2020	Dec 31, 2020	-9.8%	+33.0
Q3 FY2020	Sep 30, 2020	-67.9%	+161.1
Q2 FY2020	Jun 30, 2020	-132.6%	–
Q1 FY2020	Mar 31, 2020	-165.3%	–
Q4 FY2019	Dec 31, 2019	-42.8%	–
Q3 FY2019	Sep 30, 2019	-229.0%	–